Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.…
Wall Street Analysts Think Alpha Teknova (TKNO) Could Surge 26.41%: Read This Before Placing a Bet
Alpha Teknova (NASDAQ: TKNO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 158 employees.
The shares were at 7.630 USD on 20 November 2026, up 58.6% over 52 weeks. Its 52-week range is 1.910 USD to 9.472 USD: the price is 19.4% below the high and 299.5% above the low.
Its market capitalisation is 479.95M USD.
Alpha Teknova reports return on equity of -25.1%, an operating margin of -31.6% and revenue up 21.5% year over year.
Its debt exceeds its cash by 10.43M USD, a debt-to-equity ratio of 0.41. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock; their mean price target of 9.833 USD is 28.9% above the current price. The next earnings report is expected on 25 February 2027.